Affymax, Takeda recall anaemia drug Omontys after deaths
TOKYO Feb 24 (Reuters) - U.S. Affymax Inc. and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anaemia treatment Omontys (peginesatide) in the U.S., due to reports of serious hypersensitivity reactions, including some deaths.
As of Sunday, fatal reactions to the injection have been reported in approximately 0.02 percent of 25,000 patients after receiving their initial injection of the treatment, Affymax said in a statement.
- Atheists face death in 13 countries, global discrimination: study
- Signer says suffered schizophrenic episode at Mandela memorial |
- Missouri executes man for killing good Samaritan motorist in 1994
- Thai military chief rebuffs meeting request in blow to protesters |
- Apple scores legal victory over Samsung in South Korea